Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors

a technology of phosphodiesterase and alkyl alcohol, which is applied in the direction of drug composition, immunodeficiency, biocide, etc., can solve the problems of limited use of several pde4 inhibitors of the first-generation such as rolipram and piclamilast, and poor selectivity of compounds

Inactive Publication Date: 2013-01-10
CHIESI FARM SPA
View PDF0 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021]It is another object of the present invention to provide novel methods of preventing and / or treating of atopic dermatitis.
[0049]The present invention provides a set of potent novel PDE4 inhibitors having excellent LPDE4 selectivity.
[0050]Surprisingly, it has been found that the presence of sulphonamido substituents on the benzoate residue markedly improves the potency.

Problems solved by technology

However, corticosteroids do not reduce the inflammatory response in COPD as they do in asthma.
However, the usefulness of several PDE4 inhibitors of the first-generation such as rolipram and piclamilast has been limited because of their undesirable side effects such as nausea, gastric acid secretion and emesis due to their action on PDE4 in the central nervous system and due to the action on PDE4 in parietal cells in the gut.
However, even these compounds are not provided with a good selectivity towards LPDE4.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
  • 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors
  • 1-phenyl-2-pyridinyl alkyl alcohol compounds as phosphodiesterase inhibitors

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of 1-(3-Cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-pyridin-4-yl)-ethanol (3)

[0140]A solution of 3-cyclopropylmethoxy-4-difluoromethoxy-benzaldehyde (5.00 g) and 3,5-dichloro-4-methylpyridine (2.57 g) in 50 ml dry THF was cooled to −30° C. Solid potassium t-butoxide (tBuOK, 1.96 g) was added portionwise maintaining the temperature between −30° C. and −20° C., thus obtaining a dark red solution. After completion of the addition, the mixture was stirred at −30° C. for 1 hour. A saturated aqueous solution of NH4Cl (50 ml) was then added to the reaction mixture, maintaining the temperature between −5° C. and −10° C. The color of the reaction mixture turned to yellow.

[0141]The mixture was then extracted with EtOAc. The organic layer was dried over Na2SO4 and the solvent was removed by evaporation. The residue was treated with 30 ml of a mixture of petroleum ether / EtOAc=8 / 2; the precipitate was filtered and dried, obtaining 4.83 g of the title compound that wa...

example 2

Preparation of 1-(3-Cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethanol (4)

[0143]Compound (3) (13.0 g) was dissolved in CH2Cl2 (250 ml) then m-chloro perbenzoic acid (16.5 g) was added, and the resulting solution was stirred at room temperature for 2 hours. Na2S2O3 (25.4 g) was added, and the mixture was vigorously stirred at r.t. for 1 hour. The solid residue was filtered off, the solution was washed with 1N NaOH (3×100 ml) then the organic phase was dried over Na2SO4 and the solvent was removed by evaporation to give 10.3 g of the desired product (4) as a white solid that was used in the next steps without further purification.

[0144]MS / ESL+ 420-422 [MH]+

example 3

Preparation of Acetoxy-phenyl-acetic acid 1-(3-cyclopropylmethoxy-4-difluoromethoxy-phenyl)-2-(3,5-dichloro-1-oxy-pyridin-4-yl)-ethyl ester (5, mixture of diastereoisomers)

[0145]Compound (4) (19.95 g), (S)-acetylmandelic acid (9.22 g), 1-ethyl-3-[3-dimethylamino propyl]carbodiimide hydrochloride (18 g), and 4-dimethylaminopyridine (2.89 g) were dissolved, under N2 atmosphere, in dry CH2Cl2 (300 ml). The reaction mixture was stirred at room temperature overnight. A 5% aqueous solution of NaHCO3 (200 ml) was added and the aqueous phase was extracted with CH2Cl2 (3×100 ml). The combined organic phases were dried over Na2SO4 and the solvent was evaporated under reduced pressure to give the title compound (5) as mixture of two diastereoisomers (32 g); separation of the two diastereoisomers is described in Examples 4 and 6.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

1-Phenyl-2-pyridinyl alkyl alcohol compounds are effective as inhibitors of the phosphodiesterase 4 (PDE4) enzyme and may be used to prevent and / or treat certain diseases or conditions.

Description

CROSS REFERENCES TO RELATED APPLICATIONS[0001]This application claims priority to European Patent Application No. 09001660.1, filed on Feb. 6, 2009, which is incorporated herein by reference in its entirety.BACKGROUND OF THE INVENTION[0002]1. Field of the Invention[0003]The present invention relates to inhibitors of the phosphodiesterase 4 (PDE4) enzyme. More particularly, the invention relates to 1-phenyl-2-pyridinyl alkyl alcohol compounds, which are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme. The present invention also relates to processes for the preparation of such compounds, compositions which comprise such a compound, and combinations of such compounds. The present invention further relates to therapeutic uses of such compounds.[0004]2. Discussion of the Background[0005]Airway obstruction characterizes a number of severe respiratory diseases, including asthma and chronic obstructive pulmonary disease (COPD). Events leading to airway obstruction include oede...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/435C07D213/89A61P17/00A61K31/56A61P11/02C07D213/30A61K31/4704
CPCC07D213/61C07D213/89A61K31/44A61K31/4704C07D213/30A61M15/0065A61M16/14A61K45/06A61P11/00A61P11/02A61P11/06A61P17/00A61P37/08A61P43/00
Inventor AMARI, GABRIELEARMANI, ELISABETTADELCANALE, MAURIZIO
Owner CHIESI FARM SPA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com